A single-dose, randomized, cross-over, two-way, open-label study for comparing the absorption of boswellic acids and its lecithin formulation  by Riva, Antonella et al.
Phytomedicine 23 (2016) 1375–1382 
Contents lists available at ScienceDirect 
Phytomedicine 
journal homepage: www.elsevier.com/locate/phymed 
Original article 
A single-dose, randomized, cross-over, two-way, open-label study for 
comparing the absorption of boswellic acids and its lecithin 
formulation 
Antonella Riva a , Paolo Morazzoni a , Christian Artaria a , Pietro Allegrini a , Jürgen Meins b , 
Daniele Savio c , Giovanni Appendino d , Manfred Schubert-Zsilavecz e , Mona Abdel-Tawab b , ∗
a Indena S.p.A., Viale Ortles 12, Milano, Italy 
b Central Laboratory of German Pharmacists, Carl-Mannich-Str. 20, 65760 Eschborn, Germany 
c R&D Solution s.r.l., Via Luigi Perna, 51 00142 Roma, Italy 
d Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Via Bovio 6, 28100, Novara, Italy 
e Department of Pharmaceutical Chemistry, Goethe-University Frankfurt, Max-von-Laue Strasse 9, 60438 Frankfurt am Main, Germany 
a r t i c l e i n f o 
Article history: 
Received 12 October 2015 
Revised 24 May 2016 








a b s t r a c t 
Background: The oral administration of the gum resin extracts of Indian frankincense ( Boswellia ser- 
rata Roxb. ex Colebr) results in very low plasma concentrations of boswellic acids (BAs), being far be- 
low the pharmacologically active concentrations required in vitro for anti-inﬂammatory activity. For that 
reason the use of Indian frankincense in clinical practice and pharmaceutical development has substan- 
tially lagged behind. Recently the application of new formulation technologies resulted in a formulation 
of frankincense extract with lecithin, which revealed improved absorption and tissue penetration of BAs 
in a rodent study, leading for the ﬁrst time to plasma concentrations of BAs in the range of their anti- 
inﬂammatory activity. 
Purpose: In order to verify these encouraging results in humans, the absorption of a standardized 
Boswellia serrata extract (BE) and its lecithin formulation (CSP) was comparatively investigated in healthy 
volunteers. 
Study design: According to a randomized cross-over design with two treatments, two sequences and two 
periods, 12 volunteers alternatively received the lecithin-formulated Boswellia extract (CSP) or the non- 
formulated Boswellia extract (BE) at a dosage of 2 ×250 mg capsules. 
Methods: The plasma concentrations of the six major BAs (KBA , AKBA , βBA , αBA , A βBA , A αBA) were 
determined using LC/MS. 
Results: With the exception of KBA, a signiﬁcantly higher (both in terms of weight-to-weight and molar 
comparison) and quicker absorption of BAs from the lecithin formulation was observed, leading to C max 
in the range required for the interaction with their molecular targets. 
Conclusion: These ﬁndings pave the way to further studies evaluating the clinical potential of BAs, and 
verify the beneﬁcial effect of lecithin formulation to improve the absorption of poorly soluble phytochem- 
icals. 
© 2016 The Authors. Published by Elsevier GmbH. 
This is an open access article under the CC BY-NC-ND license 











(Abbreviations: αBA, Alpha-boswellic acid; A αBA, Acetyl- alpha-boswellic acid; 
 βBA, Acetyl- beta-boswellic acid; AKBA, Acetyl-11-keto-boswellic acid; βBA, Beta- 
oswellic acid; BAs, Boswellic acids; BE, Boswellia extract; catG, Cathepsin G; CI, 
onﬁdence interval; COX-1, Cyclooxygenase-1; ECG, Electrocardiogram; ESI, Electro 
pray Ionization; HBSAg, hepatitis B surface antigen; HCV, Hepatitis C virus; HIV, 
uman immunodeﬁciency virus; HLE, Human leuokocyte elastase; IL, Interleukin; 
BA, 11-keto-boswellic acid; LSM, Least squares means; 5-LO, 5-lipoxygenase; 
PGES-1, microsomal prostaglandin E synthase-1; NF- κB, nuclear factor-kappaB; 
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c  worldwide 25% share of the pharmaceutical arsenal ( Bhattaram et
al., 2002 ). Especially the interest in alternative, well-tolerated anti-
inﬂammatory herbal remedies has re-emerged in the last decades,
as all effort s aiming to develop safe synthetic anti-inﬂammatory
drugs are still far from achieving a real breakthrough. Gum resin
extracts of Boswellia serrata Roxb. ex. Colebr. (Indian frankincense)
have been found to represent a promising anti-inﬂammatory
herbal remedy. Numerous experimental data from in vitro studies
and animal models support the potential of boswellic acids (BAs)
( Fig. 1 ), a class of pentacyclic triterpenoids representing the major
active principles of B. serrata , for the treatment of various diseases.
Hence it was shown that a number of pivotal enzymes in inﬂam-
mation like 5-lipoxygenase (5-LO), cyclooxygenase-1 (COX-1), hu-
man leuokocyte elastase (HLE), cathepsin G (catG) and the micro-
somal prostaglandin E synthase-1 (mPGES-1) as well as the nuclear
factor-kappaB (NF- κB) and several cytokines like TNF α, IL-1 β and
IL-6 are inhibited by BAs with IC 50 values in the range of 0.6 μm to
24 μm (Abdel-Tawab et al., 2011 ; Poeckel and Werz, 2006 ). Mod-
ern research has highlighted the relevance of the whole fraction
of triterpenoid acids for the anti-inﬂammatory activity of Boswellia
extracts, since all BAs show signiﬁcant in vivo activity in animal
models of inﬂammation ( Bannoa et al., 2006 ). This represents a
dramatic change compared to the early studies, that emphasized
the relevance of a single constituent (AKBA, a minor constituent
of the BAs bouquet) and a single target (5-lipoxygenase, 5-LO)
( Safayhi et al., 1992 ). 
However, various pharmacokinetic studies in human and ani-
mals revealed very low plasma concentrations of BAs, far below
the pharmacologically active concentrations determined in vitro , in
spite of administering very high doses of Boswellia extract reaching
up to 30 0 0 mg/day ( Abdel-Tawab et el., 2011; Du et al., 2015 ). This
limited the use of B. serrata in clinical practice and pharmaceutical
development. Consequently the anti-inﬂammatory potential of BAs
could as yet not been translated into an approved clinical applica-
tion, ( Ernst, 2008 ). The dismally low oral absorption of BAs is not
surprising, since these compounds are very poorly soluble in water,
suggesting a strong tendency to self-aggregation. This hypothesis is
supported by the marked increase of absorption observed when B.
serrata extracts are administered with food, as expected from the
disruption of self-aggregates by biliary salts ( Skarke et al., 2012 ).
These considerations provided a rationale for the development of
a lecithin formulation of BAs, which revealed a signiﬁcantly im-
proved absorption of BAs accompanied with enhanced tissue pen-
etration in rats, leading for the ﬁrst time to plasma concentrations
of BAs in the range of their anti-inﬂammatory activity ( Huesch et
al., 2013 ). 
a  In the wake of these promising animal studies, we have carried
ut a comparative pharmacokinetic study in healthy volunteers
n weight-equivalent (500 mg) dosages of the lecithin-formulated
oswellia extract (CSP) and the non-formulated Boswellia extract
BE) used for its preparation. Since CSP contains only 33% Boswellia
xtract on molar basis, this involved comparison between 150 mg
f extract formulated with lecithin and 500 mg of non-formulated
xtract. 
aterials and methods 
roducts 
Gum resin extracts of Boswellia serrata Roxb. ex. Colebr. (plant
ame checked with http://www.theplantlist.org ) (Batch N.: 11239,
ode # 36BW60090) (BE) and its lecithin formulation Casperome®
Batch N.: 12146, Code # 36BWP0090) (CSP) used in the study
ere produced by Indena S.A.S. (Tours, France). Both were assigned
oucher numbers and representative voucher specimen has been
eposited in the Central Laboratory of German Pharmacists, Es-
hborn, Germany. CSP is composed of B. serrata extract and soy
ecithin in a 1:1 ratio, with about half part of microcrystalline cel-
ulose being added to improve the physical state and to standard-
ze the product to a content of total triterpenoid acids by HPLC
f at least 25%. For this study, 250 mg of BE or CSP were formu-
ated by Indena S.p.A. (Milan, Italy) into Swedish orange size “0”
ard gelatin capsules containing: 54.0 mg of corn starch and prege-
atinized starch (StarCap 1500 ®, Colorcon, UK), 50.0 mg of Citric
cid Anhydrous, 9.0 mg of Croscarmellose Sodium (Solutab ®, Blan-
er, San Paolo, Brazil), 4.0 mg of Silicon Dioxide (Syloid ® 244 FP,
. R. Grace & Co., Conn., Columbia, USA), 9.0 mg of magnesium
tearate, and 4.0 mg of talc. Before releasing the hard gelatin cap-
ules containing BE (Batch # 89035) or CSP (Batch # 89036), the
ppearance, average mass, uniformity of mass (Eur. Pharm. 2.9.1.),
PLC content of BAs, disintegration time ( < 10 min according to
ur. Pharm 2.9.1) and microbiological quality were tested. For the
etailed quantiﬁcation of the six major BAs contained in the cap-
ules see Table 1. 
ubjects 
In order to standardize all variables that may affect the pharma-
okinetics of BAs, twelve healthy non-smoking subjects aged be-
ween 20 to 51 years of Caucasian race were recruited and consid-
red eligible for enrolment as per protocol inclusion and exclusion
riteria. The screening procedures included collection of anamnesis
nd demographic data (gender, age, race, body weight [kg], height
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Table 1 
Contents of individual boswellic acids (BAs) in a single capsule of non- 
formulated Boswellia extract (BE) and lecithin-formulated Boswellia ex- 
tract (CSP). 
Boswellic Acid (BA) BE (mg per capsule) CSP (mg per capsule) 
αBA 20 .71 9 .19 
A αBA 40 .10 13 .76 
βBA 47 .28 20 .63 
A βBA 40 .01 13 .76 
KBA 16 .44 5 .81 
AKBA 12 .40 4 .11 
Total 176 .94 67 .26 
Table 2 
Overview on the demographic data of the subjects included in 
the study. 
Male Female 
Gender 6 6 
Age in years (mean ± S.D.) 33.5 ± 9.03 33.0 ± 12.02 
Weight in Kg (mean ± S.D.) 75.67 ± 7.47 57.00 ± 9.08 
Height in m (mean ± S.D.) 1.72 ± 0.06 1.60 ± 0.05 







































































































(  cm] and BMI), a physical examination, a resting 12-lead electro-
ardiogram (ECG), blood pressure, heart rate, and temperature. The
aboratory test performed included a standard urine test and clin-
cal laboratory tests (haematology, biochemistry, urinalysis, human
mmunodeﬁciency virus [HIV], hepatitis C [HCV] antibodies and
epatitis B surface antigen [HBSAg]). An overview on the demo-
raphic data of the subjects included in the study is presented in
able 2 . The volunteers received a full explanation of the nature
nd purpose of the study from the investigator in which was stated
hat they were free to withdraw from the study at any time with-
ut prejudice. Each volunteer was then required to give written in-
ormed consent for participation in the study. All the volunteers
ompleted the study and none of them referred adverse events or
igniﬁcant alteration of the hematochemical parameters, so with
eference to the safety conclusions, it is possible to assert that both
ormulations were well tolerated. 
The study was carried out in accordance with the rele-
ant guidelines of the Declaration of Helsinki (1964) and its
mendments and the general principles of ICH Harmonised Tri-
artite Guidelines for Good Clinical Practice (ICH Topic E6,
PMP/ICH/135/95, Note for Guidance on the Investigation of
ioavailability and Bioequivalence: CPMP/EWP/QWP/1401/98 Rev. 
) and Bulgaria’s legislation (LMPHM and regulation 31). The con-
uction of the clinical trial was approved by the Ethics Commit-
ee of MHAT “Lyulin” (Soﬁa - Bulgaria) with the outgoing No. 108
ated August 28th, 2014. 
tudy design 
An open-label, randomized, crossover study with two treat-
ents, two sequences and two periods was conducted, in which
he volunteers alternatively received CSP or BE according to a ran-
omization schedule. The dosage for CSP (500 mg) was selected
n the basis of a pilot human pharmacokinetic study and was in
ompliance with the rodent toxicological proﬁle of the product
not published Indena S.p.A. proprietary information). It was also
acked up by preliminary evidence of clinical activities ( Lazzaro
nd Loiero, 2014a, 2014b, 2015 ) and previous human absorption
tudies generally using similar dosages (Abdel-Tawab, 2011). As the
eight of CSP and BE contained in the two-capsule administration
as the same for both treatments, namely 500 mg, this study in-olved comparison of the formulated extract with a three-fold mo-
ar excess of the corresponding native extract. In line with the di-
ution factor associated with the presence of lecithin and micro-
rystalline cellulose in CSP the total content of the six major BAs
 Table 1 ) amounted 67.26 mg in the CSP capsule compared to
76.94 mg in the BE capsule. 
The check-in procedure was carried out at around 19:00 in the
linical center on study day -1 (the day prior to the scheduled dos-
ng of each period). After that, by 19:30 the volunteers received
 dinner and were then maintained in a fasting condition until
he study formulations (2 ×250 mg capsules) were administered as
ingle-dose with 200 ml of water between 8.00 a.m. and 9.00 a.m.
f the following day. 
Blood samples were collected before dosing (0 h) and at 0.5, 1,
.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 and 72 h post dose.
he duration of each hospitalization was about 24 h (approxi-
ately 12 h before the product administration and 12 h there-
fter) after which the volunteer was discharged. They came back
o the clinical center at 08:00 a.m. for the blood sampling of the
4, 48 and 72 h. The wash-out between treatment periods was
1 days. The volunteers had specialized attendance and cares dur-
ng all treatment periods including a summary veriﬁcation of their
onditions. 
lasma samples collection and analysis 
A total amount of about 330 ml of blood was withdrawn from
ach volunteer during the whole study. This amount includes 34
lood samples of 9 ml during the two treatment periods, and about
4 ml (2 samples of 12 ml) for laboratory tests during screen-
ng and follow-up procedures. Each sample volume was collected
nto tubes containing Li-heparine and was rapidly centrifuged at
0 0 0 rpm for 10 min. Immediately after the centrifugation ± 2.5 ml
f plasma from each sample was transferred to polypropylene
ubes and frozen at – 20 °C. For the analytical evaluation the sam-
les were transported in a frozen state to the Central Laboratory of
erman Pharmacists, Carl-Mannich-Str. 20 D-65760 Eschborn. The
ackaging of the samples met the Biosafety rules and IATA recom-
endations related to the documentation and package. 
The BAs content in plasma samples was determined using
 sensitive previously developed and validated LC-MS method
 Gerbeth et al., 2011, 2013 ). 
For that purpose, 1 ml of human plasma samples were spiked
ith 25 μl of the internal standard solution consisting of ﬂu-
xymesterone in methanol at a concentration of 4 μg/ml and 40 μl
f pure methanol (to correct for the volume in accordance with
he calibration samples). Afterwards the samples were extracted
ith THF:ethyl acetic acid: n-hexan:2-propanol (4 80:4 80:4 80:45)
nd evaporated to dryness followed by reconstitution in 100 μl
f the mobile phase. After vortexing, ultrasonic treatment, and
entrifugation LC-MS was performed on an Agilent 1200 series
quipped with a gradient pump with vacuum degasser, an au-
osampler and a column oven. A Hypersil ۛBDS RP C18 column
100 ×4 mm; 3 μm; Thermo scientiﬁc), and an upstream Gemini
ecurityGuard ۛ cartridge (Phenomenex, Germany) 4 ×3 mm were
sed for chromatography. Separation was achieved using a gra-
ient program starting with 90% mobile phase A (methanol: wa-
er 90:10, 400 mg/L ammonium formate) and 10% mobile phase B
methanol: water 80:20, 400 mg/L ammonium formate) changing
o 100% mobile phase A within 20 min. This was kept constant for
4 min before returning to the initial conditions within 1 min. The
otal run time was 35 min at a ﬂow rate of 0.4 ml/min. The col-
mn oven was set to 40 °C and the autosampler was kept at room
emperature. 
MS analysis was performed in the negative single ion mode
SIM) on an Agilent Triple Quadrupole LC/MS 6410 series
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Table 3 
Overview on the pharmacokinetic parameters of the individual BAs following the oral administration of non-formulated B. serrata extract (BE) and 
lecithin-formulated B. serrata extract (CSP) at equiweight dosage and corrected dosage (normalized pharmacokinetic parameters). 
Parameters BE (not formulated) Lecithin-formulated BE (equiweight dosage) Lecithin-formulated BE (corrected dosage) 
Mean ± SD Mean ± SD Ratio g (90% CI) h Mean ± SD Ratio (90% CI) 
KBA 
C max [ng/ml] 
a 71.12 ± 39.41 120.60 ± 57.15 1 .90 (1.26 – 2.86) ∗∗ 341.3 ± 161.73 5 .38 (3.57 – 8.10) ∗∗∗
T max [h] 
b 3.25 ± 1.20 2.75 ± 1.14 
AUC last [ng/nL 
∗h] c 980.60 ± 1376.45 1033.54 ± 1234.81 2924.9 ± 3494.5 4 .31 (2.42 – 7.68) ∗∗∗
AUC ∞ [ng/nL ∗h] d 1395.20 ± 1973.75 2050.10 ± 4237.95 5801.8 ± 11,993 3 .77 (2.07 – 6.88) ∗∗
T 1/2 [h] 
e 15.4 ± 13.49 22.84 ± 42.83 
Ke [h -1 ] f 0.08 ± 0.06 0.17 ± 0.16 
AKBA 
C max [ng/ml] 
a 6.27 ± 6.83 14.30 ± 5.78 4 .01 (1.65 – 9.78) ∗∗ 43.18 ± 17.45 11 .06 (4.28–28.55) ∗∗∗
T max [h] 
b 2.5 ± 0.91 1.27 ± 0.34 –1 .20 (–1.85 to –0.56) ∗∗
AUC last [ng/nL ∗h] c 19.35 ± 31.49 27.20 ± 17.79 3 .84 (1.28 – 11.55) ∗ 82.14 ± 53.73 10 .58 (3.35–33.41) ∗∗
AUC ∞ [ng/nL ∗h] d 38.10 ± 4 8.4 8 39.78 ± 23.68 3 .69 (1.05 – 12.94) ∗ 120.13 ± 71.52 10 .17 (2.79–37.09) ∗∗
T 1/2 [h] 
e 5.51 ± 3.11 1.78 ± 1.05 –4 .08 (–7.00 to –1.17) ∗∗
Ke [h -1 ] f 0.15 ± 0.05 0.59 ± 0.47 
βBA 
C max [ng/ml] 
a 174.94 ± 163.25 338.87 ± 140.56 2 .23 (1.67 – 2.98) ∗∗∗ 776.01 ± 321.8 5 .12 (3.83 – 6.83) ∗∗∗
T max [h] 
b 6.25 ± 2.59 4.08 ± 1.51 –2 .17 (–3.77 to –0.56) ∗∗
AUC last [ng/nL ∗h] c 3687.13 ± 3723.72 5244.78 ± 2148.64 1 .70 (1.38 – 2.10) ∗∗∗ 12,011 ± 4920.4 3 .90 (3.15 – 4.82) ∗∗∗
AUC ∞ [ng/nL ∗h] d 4438.90 ± 4398.75 6309.22 ± 2706.17 1 .68 (1.37 – 2.05) ∗∗∗ 14,448 ± 6197.2 3 .84 (3.13 – 4.70 ∗∗∗
T 1/2 [h] 
e 26.12 ± 7.35 27.01 ± 8.65 
Ke [h -1 ] f 0.03 ± 0.01 0.03 ± 0.01 
αBA 
C max [ng/ml] 
a 60.42 ± 45.60 120.24 ± 53.10 2 .16 (1.64- 2.85) ∗∗∗ 270.54 ± 119.48 4 .86 (3.68 – 6.41) ∗∗∗
T max [h] 
b 5.92 ± 2.64 3.96 ± 1.64 –1 .96 (–3.65 to –0.27) ∗
AUC last [ng/nL ∗h] c 1369.31 ± 994.62 1946.86 ± 520.72 1 .61 (1.31 – 1.97) ∗∗ 4380.4 ± 1171.6 3 .61 (2.94 – 4.44) ∗∗∗
AUC ∞ [ng/nL ∗h] d 1703.62 ± 1179.32 2610.84 ± 961.01 1 .66 (1.33– 2.08) ∗∗ 5874.4 ± 2162.3 3 .75 (2.99 – 4.69) ∗∗∗
T 1/2 [h] 
e 31.76 ± 8.57 38.58 ± 13.35 
Ke [h -1 ] f 0.02 ± 0.01 0.02 ± 0.01 
A αBA 
C max [ng/ml] 
a 119.94 ± 322.96 66.79 ± 30.12 1 .80 (1.07 – 3.03) ∗ 201.04 ± 90.66 5 .41 (3.21 – 9.13) ∗∗∗
T max [h] 
b 6.92 ± 2.02 4.96 ± 1.78 –1 .96 (–3.00 to –0.92) ∗∗
AUC last [ng/nL ∗h] c 2022.55 ± 5228.92 1202.17 ± 521.45 1 .68 (1.05 – 2.68) ∗ 3618.5 ± 1569.5 5 .04 (3.16 – 8.06) ∗∗∗
AUC ∞ [ng/nL ∗h] d 2339.48 ± 6022.60 1413.35 ± 562.18 1 .70 (1.07 – 2.69) ∗ 4254.2 ± 1692.1 5 .11 (3.23 – 8.09) ∗∗∗
T 1/2 [h] 
e 23.55 ± 6.55 28.06 ± 10.84 
Ke [h -1 ] f 0.03 ± 0.01 0.03 ± 0.01 
A βBA 
C max [ng/ml] 
a 100.44 ± 133.61 173.75 ± 68.44 2 .29 (1.61 – 3.24) ∗∗ 505.62 ± 199.16 6 .66 (4.69 – 9.44) ∗∗∗
T max [h] 
b 5.92 ± 1.68 4.29 ± 1.50 –1 .62 (–2.76 to –0.49) ∗∗
AUC last [ng/nL ∗h] c 1722.25 ± 2555.58 2465.55 ± 895.85 1 .99 (1.44 – 2.76) ∗∗ 7174.8 ± 2606.9 5 .80 (4.20 – 8.03) ∗∗∗
AUC ∞ [ng/nL ∗h] d 2013.22 ± 3099.16 2743.74 ± 975.76 1 .94 (1.38 – 2.72) ∗∗ 7984.3 ± 2839.4 5 .65 (4.03 – 7.93) ∗∗∗
T 1/2 [h] 
e 23.57 ± 7.65 22.09 ± 6.10 
Ke [h -1 ] f 0.03 ± 0.01 0.03 ± 0.01 
a C max : maximal plasma concentration calculated as mean of the individual maximal plasma concentrations of each subject; 
b T max : time required 
to C max ; 
c AUC last : area under the plasma concentration–time curve calculated by trapezoidal rule from time zero to the time of the last quantiﬁable 
concentration; d AUC ∞ : area under the plasma concentration–time curve calculated by trapezoidal rule from time zero extrapolated to inﬁnite time; 
e T 1/2 : the mean time taken for the plasma concentration to fall to half of its original value; 
f Ke: Elimination rate constant from the central compart- 
ment; g Ratio: geometric mean ratio of lecithin-formulated BE (equiweight dosage) to non-formulated BE; 90% h CI: 90% conﬁdence interval; statistically 
signiﬁcant differences: ∗ means P < 0.1; ∗∗ means P ≤ 0.05; ∗∗∗ means P ≤ 0.001. Note that the maximal plasma concentrations in the table may differ 


























L  (Agilent Technologies, Waldbronn, Germany) equipped with an
Electro Spray Ionization source (ESI). Dwell time was chosen to
be 200 ms. The detected ions in single ion mode were m/z 511.5
for AKBA, m/z 469.3 for KBA, m/z 497.4 for A αBA and A βBA, re-
spectively, m/z 455.5 for αBA and βBA, respectively, and m/z 381.2
for the internal standard ﬂuoxymesterone. Quantiﬁcation of plasma
samples was carried out with the internal standard method using
peak area ratios. A chromatographic run consisted of the calibra-
tion samples, the quality control samples and the respective vol-
unteer samples. The MassHunter® software was used for data ac-
quisition and processing. 
Pharmacokinetic analysis 
All subjects completed the two treatment periods without any
major protocol deviation and were therefore included into the sta-istical analysis. The pharmacokinetic parameters have been calcu-
ated using the software SAS ® (Statistical Analysis System) version
3 and EquivTest/Pk. 
tatistical analysis 
All plasma data for the individual BAs were expressed as mean
S.D. For statistical analysis the pharmacokinetic parameters
AUC last , AUC ∞ and C max ) derived from the plasma concentrations
f the individual BAs have been log-transformed and analyzed by
ixed-effects ANOVA according to a two-treatment, two-period,
wo-sequence randomized crossover design. The ANOVA model in-
luded Treatment, Period and Sequence as ﬁxed factors and Vol-
nteers nested in sequences as random factor. The least squares
eans (LSM) of CSP and BE and the difference (CSP-BE) between
SM with the 90% conﬁdence interval (90% CI) have been calcu-
A. Riva et al. / Phytomedicine 23 (2016) 1375–1382 1379 
Fig. 2. Plasma concentrations of boswellic acids (BAs) after single oral administration of the non-formulated extract (BE-series) and their corresponding lecithin formulation 









N  ated. The CSP/BE ratio was found by calculating the anti-log of the
ifference between LSM. ANOVA was also performed on the un-
ransformed data of the other pharmacokinetic parameters: T max ,
 1/2 and Ke. The difference between LSM and the 90% CI have been
eported. esults and discussion 
The mean plasma concentrations and pharmacokinetic pa-
ameters of each individual BA are summarized in Table 3 .
otably, the administration of the non-formulated BE was asso-
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c  ciated with a higher variability compared to the administration
of the lecithinized CSP formulation. This may be attributed to
the high interindividual variability often noted in pharmacoki-
netic studies upon administration of sparingly soluble and poorly
bioavailable compounds. Nevertheless, in spite of this great vari-
ability, a clear conclusion could be made upon statistical analysis.
As reﬂected by the geometric mean ratio of CSP to BE, found by
calculating the anti-log of the difference between LSM, the admin-
istration of CSP at equivalent weight dosage resulted in statistically
higher C max and AUC for AKBA (4-fold), and A βBA, βBA , αBA , and
A αBA (2-fold), while only a modest increase for the C max (10%) and
no signiﬁcant change in the AUC was observed for KBA. These re-
sults clearly demonstrate an enhanced absorption of BAs from theecithinized CSP formulation compared to the non-formulated BE
ven though the administered amount of B. serrata extract in CSP
orresponded only to around one third of the amount of B. ser-
ata extract in the BE formulation. In addition the absorption was
bout 1.5–2 h faster in case of the lecithin formulation compared
o the non-formulated extract ( Table 3 ) for all BAs that showed an
mproved absorption. 
The increased absorption of BAs from CSP manifests itself also
n the higher plasma concentration proﬁles presented in Fig. 2 a-
. Only the C max of A αBA ( Fig. 2 c), in contrast to the other
As, was higher in the BE formulation. This may be simply at-
ributed to a particularly high value determined for the plasma
oncentration of A αBA in one subject of the BA group, resulting





















































































































 n an overall increased mean C max for A αBA in the BE group. Since
owever, this aberrant value could not be ascribed to an analyt-
cal mistake, it wasn’t eliminated. Notably, the plasma concentra-
ion proﬁles of the non-acetylated BAs KBA, βBA, and αBA re-
eal multiple peakings in the plasma concentration over time. This
henomenon is often encountered in case of enterohepatic circu-
ation. In this case extensively metabolized drugs are transported
rom the liver to the small intestine via the bile duct, where they
re subsequently reabsorbed back through the lumen of the gas-
rointestinal tract into the portal blood circulation ( Davies et al.,
010 ). In fact, it could be shown that the non-acetylated BAs KBA,
BA, and αBA undergo extensive metabolism, whereas the acety-
ated BAs AKBA, A βBA, and A αBA are rather metabolically stable
 Gerbeth et al., 2013 ). In order to get an approximate idea of the
harmacokinetics of BAs in case an equimolar amount of the BAs
n the non-formulated extract would have been administered as
ecithin formulation, the pharmacokinetic data (C max , AUC last , and
UC ∞ ) were normalized taking into consideration the dilution fac-
or for the respective BA in the lecithin formulation. Also the ex-
rapolated data revealed an improved BA absorption ( Table 3 cor-
ected dosages), being highest for AKBA (almost 10-to 11-fold in-
rease in Cmax and AUC), and signiﬁcant for A αBA and A βBA (5-
old improvement). Although not so marked, also the increase for
BA, βBA and KBA could compensate the almost 1:3 dilution ef-
ect of lecithin addition. This signiﬁcant improvement in the ab-
orption of acetylated BAs is unique to the present study and could
ot be observed before, even when BAs were administered with a
atty meal ( Skarke et al., 2012 ). Obviously the acetylation of the 3-
ydroxyl group in BAs exerts a remarkable effect on the enhanced
ecithin-associated absorption of BAs. Of course, a precise evalua-
ion of the improved absorption associated to the lecithin formu-
ation would have involved an equimolar comparison between the
mounts of BAs administered as formulated and non-formulated
xtract. But as further clinical studies are planned, we had opted
or a more practical weight-to-weight comparison when designing
he present study. Nevertheless, the present study revealed for the
rst time in human studies, plasma levels in the range of the active
oncentrations of BAs after a single administration of a Boswellia
xtract. Thus, the C max values of βBA, and A βBA were found to
all in the range of their IC 50 values (0.8 μM, 1.2 μM, respectively)
or the inhibition of cathepsin G, a major target of Boswellia triter-
enoids ( Tausch et al, 2009 ). The C max value of βBA was also in
he range of the IC 50 (1.8 μM) value for the inhibition of LPS ac-
ivity in a cell-free LAL assay ( Henkel et al., 2012 ). On the other
and, even though AKBA mostly beneﬁted in terms of absorption
rom the lecithin formulation, its plasma concentration (C max 0.03
M) remained below its pharmacological activity range. Based on
he fact that the pharmacological activity of Boswellia extract can-
ot be assigned to a single BA, our results underlie the relevance of
ecithin formulation to improve the absorption of the whole mul-
icomponent botanical extract and not just of speciﬁc constituents.
his is reﬂected in the enhanced absorption of the whole BA bou-
uet in the present study as well as in the improved absorption of
 lecithin formulation of curcuminoids in a former study ( Cuomo
t al., 2011 ). However excipient enhancers should not be evaluated
nly in terms of improved molar absorption of an active, but also
n terms of their added weight to the ﬁnal formulation, as the
verall weight of a formulation (tablets, capsules, soft gels) rep-
esents a critical parameter in formulation development and ad-
inistration. Also in this regard the lecithin formulation provides a
reat advantage. Hence the weight of the adsorption (lecithin)- and
ormulation (cellulose) adjuvants is kept within reasonable limits
about 2/3 of the ﬁnal product) in the lecithin-formulated Boswellia
xtract , allowing thus the extract’s use in a ﬁnished solid product
orm. This remarkable technological achievement is of special rel-
vance for herbal extracts that are often sticky resinous materialsequiring normally a high load of additives to be formulated into
olid forms (capsules, tablets, soft gels). 
onclusion 
In summary, the present study revealed an enhanced absorp-
ion of BAs from the lecithin formulation, resulting for the ﬁrst
ime in plasma concentrations in the range of their pharmacolog-
cally active concentrations. These promising results pave the way
o more clinical studies in the future evaluating the clinical po-
ential of BAs. Last but not least, the present study supports the
eneﬁcial effect of emulsiﬁcation with lecithin on the absorption
f strongly self-aggregating and poorly soluble phytochemicals, by
imply mimicking the natural absorption process of a fatty meal. 
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